x

Uncategorized Archives – #BCSM

Sexual Health after Breast Cancer Treatment
By: bcsmadmin
Oct 23, 2020

October 23, 2020 Join us Monday 10/28/2020 when our guest Dr. Sharon Bober (@DrSharonBober) will lead a discussion on sexual health and changes in sexual function due to breast cancer therapy. Dr. Bober is the founder and director of the Dana Farber Cancer Institute Sexual Health Program, and is an Assistant Professor of Psychiatry at the Harvard […]

Read more ›
BCSM
COVID19 – Check In Sessions
On: Mar 23, 2020
By: Alicia

Hi everyone – given the fast pace of breaking news, we’re launching more regular checkins for the next few weeks. In addition to the regular Monday Night Tweet chats, we’re adding a weekly ZOOM Check in call on Wednesday and Thursday. This will allow the #BCSM Community members come together on a regular basis and […]

Read more ›
ASBrS 2017 – Key Topics by Dr. Deanna Attai
On: May 8, 2017
By: Alicia

Dr. Shelley Hwang from Duke University spoke on DCIS subtyping and overtreatment. She noted that DCIS now comprises over 20% of all mammographically detected breast cancer. It is considered a “non-obligate precursor” of invasive cancer – the rate and likelihood of progression to invasive cancer are not clearly known. However, it is clear that some […]

Read more ›
ASBrS 2017: Oncoplastics and Adequate Margins
On: May 8, 2017
By: Alicia

This guest post is from Dr. Aleksandra Popadich.  Dr. Popadich came all the way to Las Vegas from New Zealand because she watched Dr. Attai’s tweets from the 2016 conference! Oncoplastic surgery is going to become a part of breast surgeon’s repertoire. The development of these skills will enable us to achieve good local control and […]

Read more ›
ASBrS 2017: Contralateral Prophylactic Mastectomy (CPM)
On: May 8, 2017
By: Alicia

ASBrS17: Contralateral Prophylactic Mastectomy (CPM) This guest post is by Dr. Diane Radford. The American Society of Breast Surgeons published a consensus statement on CPM in which it was stated that average-risk women with unilateral breast cancer do not derive any oncologic benefit from CPM, and thus CPM should be discouraged (Annals of Surgical Oncology […]

Read more ›